RxDoctor Payments DataLook up a doctor →

Karen Schwartz, MD

Endocrinology, Diabetes & Metabolism · Woodbury, NYNPI 1225119241

Payments from drug & device makers

$278,045in general payments, 2019–2025

Across 1,301 payments — averaging $213.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$238K
  • Astellas Pharma US Inc$17K
  • AMAG Pharmaceuticals, Inc.$4K
  • Bayer$2K
  • Amgen$2K
  • Insulet Corporation$2K
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC493$237,677
Astellas Pharma US Inc28$16,839
AMAG Pharmaceuticals, Inc.11$4,203
Bayer19$2,259
Amgen(2 entities)76$1,825
Insulet Corporation15$1,804
Amneal Pharmaceuticals LLC78$1,629
Novo Nordisk75$1,336
Boehringer Ingelheim55$1,285
Radius Health, Inc.64$1,207
AbbVie66$1,011
Sanofi-aventis U.S. LLC45$947
Mannkind Corporation41$863
Xeris Pharmaceuticals, Inc.26$545
Abbott17$519
Millicent US Inc16$325
Corcept Therapeutics14$300
Therapeuticsmd, Inc.12$228
Dexcom, Inc.12$213
Biohaven Pharmaceuticals, Inc.2$200
Pfizer8$189
AstraZeneca(2 entities)10$183
IBSA Pharma Inc.10$183
Myovant Sciences Inc.7$173
Medtronic(2 entities)7$139
Merck8$137
Optinose US, Inc.2$125
Vivus LLC6$122
Ascendis Pharma Endocrinology Inc6$117
Intuity Medical Inc6$111
Mayne Pharma Commercial LLC5$95
Regeneron Healthcare Solutions, Inc.1$90
Currax Pharmaceuticals LLC5$87
Amarin Pharma, Inc.4$86
Johnson & Johnson4$78
Sumitomo Pharma America, Inc.3$78
Shire North American Group Inc4$67
Novartis2$56
Ultragenyx Pharmaceutical Inc.3$56
Tolmar, Inc.3$55
Alfasigma USA, Inc.2$42
Vertical Pharmaceuticals, LLC3$39
Virtus Pharmaceuticals LLC2$34
Avion Pharmaceuticals2$34
Esperion Therapeutics, Inc.2$31
Tandem Diabetes Care, Inc.1$29
Vistapharm, Inc.2$26
Bigfoot Biomedical Inc1$26
Ionis Pharmaceuticals, Inc.1$26
Galderma Laboratories, L.p.1$24
Dermira, Inc.1$24
Almatica Pharma LLC1$23
Madrigal Pharmaceuticals1$23
Acella Pharmaceuticals, LLC1$22
BETA Bionics, Inc.1$22
Sequel Med Tech, LLC1$22
Collegium Pharmaceutical, Inc.1$20
Antares Pharma, Inc.1$20
Kowa Pharmaceuticals America, Inc.1$20
Amryt Pharma Holdings Ltd1$19

How this compares

$278,045 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York →

Medicare billing

Part B allowed, 2024
$602,113
Medicare patients
999
Services billed
9,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Woodbury

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →